1_2_our_history-itok=956gTx3C

Where We Started.
Where We Are Headed.

We have dedicated ourselves to helping people who face life-threatening illnesses. Our focus has been on cancer, and we will continue to specialize in developing revolutionary cancer treatments as well as therapies for immune-mediated inflammatory diseases.

No challenge is too big. We are creating a pipeline that strives to yield ground-breaking advancements and life-changing therapies.

2015

IMBRUVICA® receives esteemed 2015 Prix Galien award for Best Pharmaceutical Agent, as voted on by a committee of 10 renowned leaders from the biomedical industry and academia.

2015

On January 29, IMBRUVICA® receives FDA approval for its fourth indication for the treatment of patients with Waldenström’s macroglobulinemia (WM). This approval represents the first therapy indicated specifically for patients with WM, a rare, indolent type of B-cell lymphoma.

2015

AbbVie completes the acquisition of Pharmacyclics, Inc., valued at $21B, on May 26. Pharmacyclics becomes a wholly-owned subsidiary of AbbVie, maintaining its headquarters in Sunnyvale, CA.

2014

Pharmacyclics is named 2014 Company of the Year by BayBio, representing 1,000 life sciences companies and institutions in Northern California, for exceptional success with IMBRUVICA® in a relatively short amount of time. Each year, one company that has made the greatest advancement and/or greatest overall contribution to the area’s life sciences industry is independently nominated and selected for this honor.

2014

Pharmacyclics wins prestigious 2014 Society for Medicines Research Award for Drug Discovery for ibrutinib discovery. The independent research award recognizes outstanding development and is bestowed upon compounds with a novel mechanism of action and molecular interaction principle, high degree of clinical benefit, and significant ability to address unmet medical needs.

2014

A supplemental New Drug Application for IMBRUVICA® is submitted to the U.S. FDA for the treatment of Waldenström’s macroglobulinemia (WM).

2014

The IMBRUVICA® Phase III Clinical Development Program is still rich and deep, consisting of 13 Phase III trials across a variety of B-cell malignancies of which 3 are investigator-sponsored trials (ISTs).

2014

IMBRUVICA® receives marketing approval by the European Commission for the treatment of relapsed or refractory MCL patients, chronic lymphocytic leukemia (CLL) patients who have received at least one prior therapy, or first-line CLL patients in the presence of 17p deletion (del 17p) or TP53 mutation in patients unsuitable for chemotherapy.

2014

Single-agent IMBRUVICA® receives FDA approval on July 28 for its third indication for the treatment of CLL patients with deletion of the short arm of chromosome 17 (del 17p), and becomes the first medicine approved to treat del 17p CLL.

2014

IMBRUVICA® receives full FDA approval on July 28 as a single-agent treatment for CLL patients who have received at least one prior therapy

2014

IMBRUVICA® receives FDA approval on February 12 as a single agent for its second indication for the treatment of CLL patients who have received at least one prior therapy. (This indication was based on overall response rate. An improvement in survival or disease-related symptoms had not been established)

2013

The Phase III Clinical Development Program for IMBRUVICA® continues with five additional trials, for a total of 10 Phase III trials, of which 1 is an IST

2013

IMBRUVICA® receives FDA approval on November 13-as a single agent for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy. This indication was based on overall response rate. An improvement in survival or disease-related symptoms had not been established.

2013

A New Drug Application and Marketing Authorization Application are submitted to the U.S. FDA and to the European Medicines Agency, respectively, for ibrutinib for two relapsed/refractory B-cell malignancy indications: MCL and CLL/SLL

2013

Ibrutinib becomes one of the first compounds to receive the U.S. FDA’s new Breakthrough Therapy Designation (BTD) for CLL/small lymphocytic lymphoma (SLL) with del 17p, relapsed/refractory MCL and WM, and the only compound to receive three BTDs.

2012

Initiated Phase III Clinical Development Program for ibrutinib in partnership with Janssen Biotech that consists of five Phase III trials.

2012

Critical Phase II ibrutinib data show prolonged duration of response in CLL and MCL.

2011

Initiated Phase II ibrutinib studies in several B-cell malignancies.

2011

Partnered with Janssen Biotech, Inc. to co-develop and commercialize ibrutinib in oncology.

2010

Initiated Phase II studies in CLL/SLL.

2010

Present proof-of-concept data for ibrutinib in CLL and MCL at the American Society of Hematology meeting.

2009

Initiated the first BTK inhibitor (ibrutinib) trials in CLL, MCL, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), WM and other B-cell malignancies.

2006

In-licensed the BTK Inhibitor, HDAC Inhibitor & Factor VIIa Inhibitor from Celera, expanding the oncology pipeline.

1995

Became a publicly traded company on NASDAQ (PCYC).

1991

Founded to resolve the unmet needs of cancer patients.